Researchers in industry focus on practical applications of fairness, while those in academia may take a broader perspective but rely on industry connections.

Thirty years ago, the interests of basic science and industry were quite different, but today they heavily overlap, with both fields focusing on similar questions and challenges.

There's increasing acceptance of transitioning from academia to industry, as innovations often stem from academic research, and pursuing entrepreneurship can be a viable path for scientists. Most drugs on the market originate from discoveries made in academia, which are then commercialized by biotech or pharmaceutical companies.

Staying in academia can be risky due to job uncertainty, making entrepreneurship an appealing alternative for many researchers.

As industries mature, they often shift from a middle-ground strategy to a 'barbell' strategy, where companies either operate at high scale or as specialized boutiques.

At Arc Institute, we blend our academic side with a technical staff structured more like industry, aiming to create a model that others might want to replicate.

In academia, there is less focus on hardcore drug manufacturing aspects like pharmacokinetics or toxicology, but there is significant interest in molecular glues, machine learning models, and new drug concepts.

Investors often have different incentives than founders, which can lead to misalignment in priorities.

The structure of competition in industries often prevents innovators from making money, despite creating significant value for society.